Table 2 Circulating cfDNA In Hepatocellular Carcinoma
Ref. | Patients (HCC) | Ethnicity | Blood sample | Controls | Measure methods | Target site | Positive rate |
|---|---|---|---|---|---|---|---|
Ren N et al., 2006 [71] | 79 | China | Plasma | 40 (LC: 20; HV: 20) | Quantitative analysis Real-Time PCR | Chromosome 8p | NA |
Iizuka N et al., 2006 [72] | 60 | Japan | Serum | CLD: 30 | Quantitative analysis Real-Time PCR | GSTP1 | NA |
Yang Y et al., 2011 [73] | 60 | China | Plasma | 50 (CLD: 21; HV: 29) | Quantitative analysis FQ-PCR | hTERT | NA |
Huang Z et al., 2012 [74] | 72 | China | Plasma | 78 (LC: 72; HV: 41) | Quantitative analysis Real-Time PCR | Beta-Actin | NA |
Piciocchi M et al., 2013 [75] | 66 | Italy | Plasma | 76 (LC: 35; CLD: 41) | Quantitative analysis Real-Time PCR | hTERT | NA |
Huang A et al., 2016 [76] | 53 | China | Plasma | 16: OLT | Quantitative analysis Real-Time PCR | ALU | NA |
Yan L et al., 2017 [77] | 24 | China | Plasma | 62: CLD | Quantitative analysis Qubit Assay | NA | NA |
Wong, I. H et al., 2000 | 25 | China | Plasma /Serum | 55 (LC: 35; HV: 20) | Methylation MS-PCR | P15 P16 | 64% 48% |
Wong, I. H et al., 2003 | 29 | China | Plasma | CLD: 50 | Methylation MS-PCR | P16INK4a | 80% |
Yeo, W et al., 2005 [86] | 40 | United Kingdom | Plasma | HV: 10 | Methylation MS-PCR | RASSF1A | 92% |
Zhang YJ et al., 2007 [79] | 50 | China | Plasma | HV: 50 | Methylation MS-PCR | RASSF1A P15 P16 | 70% 22% 44% |
Chang Hong et al., 2008 [85] | 26 | China | Plasma | CLD: 16 | Methylation MS-PCR | P16 GSTP1 RASSF1A APC | 19% 19% 26% 61% |
Chan, K. C et al., 2008 [87] | 63 | China | Serum | HV: 50 | Methylation MS-PCR | RASSF1A | 93% |
Iyer, P et al., 2009 | 150 | Egypt | Plasma | HV: 150 | Methylation MS-PCR | APC FHIT P15 P16 | 53% 67% 10% 46% |
Huang, Z. H et al., 2011 [82] | 72 | China | Plasma | HD: 37 | Methylation MS-PCR | APC GSTP1 RASSF1A SFRP1 | 68% 55% 72% 55% |
Iizuka, N et al., 2011 [81] | 108 | Japan | Serum | CLD: 56 | Methylation MS-PCR | BASP1 CCND2 APC SPINT2 SRD5A2 CFTR RASSF1A | 62% 64% 17% 35% 8% 56% 92% |
Sun, F. K et al., 2012 [84] | 43 | China | Serum | 50 (CLD: 24; HV: 26) | Methylation MS-PCR | TFPI2 | 46% |
Zhang, P et al., 2013 [89] | 31 | China | Serum | HV: 21 | Methylation MS-PCR | DBX2 THY1 | 88% 85% |
Han, LY et al., 2014 [90] | 160 | China | Serum | 133 (CLD: 88; HV: 45) | Methylation MS-PCR | TGR5 | 48% |
Ji, XF et al., 2014 [91] | 121 | China | Serum | 69 (CLD: 37; HV: 31) | Methylation MS-PCR | MT1M MT1G | 48% 70% |
Huang, G et al., 2014 [92] | 66 | United States | Serum | CLD:43 | Methylation MS-PCR | INK4A | 65% |
Wen Lu et al., 2015 | 36 | China | Serum | 55 (LC: 17; HV: 38) | Methylation MS-PCR | RGS10 ST8SIA6 RUNX2 VIM | 94% |
Xu RH et al., 2017 [93] | 1098 | China | Plasma | HV: 835 | Methylation MS-PCR | Diagnostic panel (10) Prognostic panel (8) | 85% |